Lafepe

What Lafepe does

Lafepe (Laboratório Farmacêutico do Estado de Pernambuco Governador Miguel Arraes S/A) is a Brazilian state-owned pharmaceutical laboratory founded in 1965 and headquartered in Recife, Pernambuco. The company develops, produces, and commercializes medicines and eyeglasses, operating a modern industrial park with three production divisions (Sólidos I, Sólidos II, and DICEM) plus a new Industrial Unit and R&D Center inaugurated in 2023. Its portfolio centers on essential public-health medicines, including Benznidazol for Chagas disease (for which it is the sole worldwide manufacturer under a Roche technology transfer), antiretrovirals (Dolutegravir, Ritonavir, AZT, Lamivudine, and others), tuberculostatics (approximately 70% of Ministry of Health national supply), antipsychotics, and a consumer supplement line led by Vitamin C. Technology infrastructure includes electrodeionization-based water treatment, ANVISA-certified Good Manufacturing Practices (BPF/GMP), rigorous multi-stage quality control, and a permanent pharmacovigilance customer service channel.

The business model is anchored on long-term government procurement through Brazil's Sistema Único de Saúde (SUS) and Parcerias para o Desenvolvimento Produtivo (PDP) partnerships with private firms such as Blanver (Dolutegravir), Cristália (Ritonavir), and historically Roche (Benznidazol). Under these PDPs, the private partner initially supplies finished product while Lafepe progressively absorbs technology over a multi-year period, enabling fully domestic production. Lafepe's primary customer is the Brazilian Ministry of Health, which procures essential medicines for nationwide distribution. A secondary retail channel consists of Lafepe's own pharmacy network of 32+ units across Recife, the Metropolitan Region, and the interior of Pernambuco, which sells Lafepe-manufactured medicines and eyeglasses directly to consumers at subsidized prices. The company employs 11–50 staff per firmographic data (though recent public competitions indicate ongoing workforce expansion) and reports no private shareholders, operating instead as an autonomous state entity under the Government of Pernambuco with a public-health mandate rather than a profit-maximization objective.

Name

Lafepe

Legal name

Laboratório Farmacêutico do Estado de Pernambuco Governador Miguel Arraes S/A

Website

https://lafepe.pe.gov.br

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

11–50 employees

Short description

Lafepe is a Brazilian state-owned pharmaceutical laboratory founded in 1965 that develops, produces, and supplies essential medicines (antiretrovirals, tuberculostatics, Benznidazol for Chagas disease) to the Ministry of Health via Brazil's SUS, and sells supplements and eyeglasses through its own pharmacy network across Pernambuco.

Ownership category

akta.pro rank

Headquarters

HQ city

Olinda

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D

Revenue model

1. Public Health System Sales (SUS / Ministry of Health): Lafepe's primary revenue stream derives from supplying essential medicines to the Brazilian Ministry of Health and the Sistema Único de Saúde (SUS) through contracted procurement agreements, including Parcerias para o Desenvolvimento Produtivo (PDP).
2. Own Pharmacy Network Sales: Medications and ophthalmic products are sold directly to the public at low cost through Lafepe's own pharmacy network installed across Recife, the Metropolitan Region, and the interior of Pernambuco.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Lafepe develops, manufactures and distributes essential medicines — including antiretrovirals (Dolutegravir, Ritonavir, AZT, Lamivudine, Stavudine, Indinavir, Ganciclovir), tuberculostatics, antipsychotics, the sole-supply Benznidazol for Chagas disease, nutritional supplements, and in-house manufactured eyeglasses — primarily to the Brazilian Ministry of Health and SUS through government contracts and PDPs, and additionally to consumers via its own retail pharmacy network across Pernambuco.

Product overview

Lafepe (Laboratório Farmacêutico do Estado de Pernambuco – Governador Miguel Arraes) is a state-owned pharmaceutical laboratory founded in 1965, operating as a single unified enterprise that develops, produces, and commercializes medicines and eyeglasses for public health policies in Pernambuco, Brazil. The product portfolio centers on five core pharmaceutical lines: (1) Benznidazol 100 mg for Chagas disease, the only supplier in Brazil for the Ministry of Health; (2) antiretrovirals including Dolutegravir 50 mg, Ritonavir 100 mg, and others (AZT, Lamivudine, Stavudine, Indinavir, Ganciclovir) for HIV/AIDS treatment via PDPs; (3) antipsychotics (Olanzapine, Clozapine, Quetiapine Hemifumarate) for mental health conditions; (4) tuberculostatics (Isoniazida+Rifampicina, Pirazinamida, Isoniazida) covering approximately 70% of Brazil's Ministry of Health needs; and (5) supplements including Vitamin C (the flagship product), with new lines of Vitamin D3, Calcium Carbonate+Vitamin D3, multivitamins, and omega-3 planned for 2024 launch. Beyond pharmaceuticals, Lafepe manufactures and retails its own line of eyeglasses through a network of Lafepe Pharmacy stores across Pernambuco. Lafepe also conducts R&D collaborations with UFPE for new drug formulations including hanseníase treatment (expected by end of 2025). The company operates one of the largest pharmaceutical production facilities in Pernambuco, with modernized infrastructure including a new industrial unit inaugurated in 2023.

Differentiator

Problem solved

Functional benefit

Brands

• Vitamina C Lafepe: Vitamin C supplement, one of the company's flagship products sold through its pharmacy network.
• LAFEPE Ótica

Products and services

• Benznidazol 100 mg Oral medication for the treatment of Chagas disease, produced exclusively by Lafepe in Brazil under a Roche technology transfer. It is the only Benznidazol manufacturing source worldwide, supplied to the Ministry of Health for distribution through SUS, and includes a pediatric formulation for Chagas disease treatment.
• Dolutegravir 50 mg (anti-HIV) Antiretroviral (integrase inhibitor) for HIV treatment in combination with other agents. Produced in Brazil through a PDP with Blanver Farmoquímica. Indicated for adults and children at least six years old weighing more than 20 kg, and forms part of the 22-drug cocktail used against AIDS in Brazil's SUS program.
• Ritonavir 100 mg (anti-HIV) Antiretroviral medication used in combination therapy for HIV-1 treatment, supplied through a PDP with Cristália Produtos Químicos Farmacêuticos Ltda., with ANVISA-recognized exclusive production at either Lafepe's plant or Cristália's plant. Contract unit price R$ 1.065 per tablet under the 2026/2027 Ministry of Health contract.
• Antiretroviral portfolio (AZT, Lamivudine, Stavudine, Lamivudine+Zidovudine, Indinavir, Ganciclovir) Solid-dose antiretroviral medicines for HIV/AIDS treatment, supplied to the Ministry of Health for distribution through SUS. Lafepe was the first Brazilian laboratory to produce AZT and supplies a substantial part of Brazil's HIV cocktail.
• Antipsychotics (Olanzapine, Clozapine, Quetiapine Hemifumarate) Antipsychotic medications for mental health conditions including schizophrenia, bipolar disorder, manic episodes, and depression. Portfolio includes Olanzapine 5 mg and 10 mg, Clozapine 25 mg and 100 mg, and Quetiapine Hemifumarate 25 mg, 100 mg, and 200 mg, supplied to SUS programs for mental health treatment.
• Tuberculostatics (Isoniazida+Rifampicina, Pirazinamida, Isoniazida) Anti-tuberculosis medicines manufactured by Lafepe and supplied to the Brazilian Ministry of Health's National Tuberculosis Program, covering approximately 70% of the federal tuberculostatics demand. Products include fixed-dose combinations and single-drug presentations of Isoniazida, Rifampicina, and Pirazinamida.
• Vitamin C supplement Over-the-counter Vitamin C supplement manufactured by Lafepe and sold at subsidized prices through Lafepe's pharmacy network. One of Lafepe's flagship consumer products.
• Eyeglasses (Óculos) Eyeglasses manufactured in-house at Lafepe's industrial park and sold at low, subsidized cost through Lafepe's pharmacy network to improve access to corrective lenses for low-income populations in Pernambuco.
• Lafepe Pharmacy Network (Farmácias Lafepe) Retail pharmacy service operating 32+ owned stores across Pernambuco (Recife, Metropolitan Region, and Interior). Sells Lafepe-manufactured medicines and eyeglasses at subsidized prices directly to the general public.

Quantifiable outcome

• 43% reduction in energy costs, saving R$ 1.2 million per year
• +4 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Cristália Produtos Químicos Farmacêuticos Ltda.coreTechnology or Integration · 19 June 2026Cristália is the technology transferor for LAFEPE RITONAVIR 100 mg as part of a PDP arrangement recognized by ANVISA. Per the inexigibility ratification, medications produced under this PDP must be manufactured exclusively at either Lafepe's plant or Cristália's plant. Contract value: R$ 1.065 per unit.
• Copergás (Companhia Pernambucana de Gás)coreStrategic or Co-development Partner · 18 April 2024Copergás installed a natural gas pipeline to supply Lafepe's industrial park for steam generation, replacing BPF oil. The fuel is used in the Divisões de Sólidos I and II, with monthly consumption of ~16,500 m³. The partnership enables Lafepe to achieve 43% reduction in energy costs (R$ 1.2 million/year savings) and aligns with the state's decarbonization and energy efficiency policy.
• UFPE (Universidade Federal de Pernambuco)coreStrategic or Co-development Partner · 1 January 2024Lafepe is collaborating with UFPE on an innovative R&D project to develop new medications associated with the treatment of leprosy (hanseníase), covering both adult and pediatric patients. The project is expected to conclude by the end of 2025.
• Ministério da Saúde (Ministry of Health of Brazil)coreStrategic or Co-development Partner · 1 January 2024Lafepe's most important strategic partner. The Ministry of Health procures essential medicines from Lafepe through SUS and enters into PDPs for technology absorption and local production. Together they have faced major public health challenges including HIV/AIDS, tuberculosis, Chagas disease, and leprosy.
• Blanver Farmoquímica e FarmacêuticacoreStrategic or Co-development Partner · 24 March 2022Through a Parceria para o Desenvolvimento Produtivo (PDP), Blanver and Lafepe are producing Dolutegravir 50 mg — a 100% Brazilian anti-HIV medication — at scale (79.5 million tablets/year). The PDP includes technology transfer over a five-year period: Blanver delivers finished product initially, and Lafepe progressively internalizes the full production process by 2026. CYG Biotech (part of Blanver) and Nortec Química nationalize the IFA (Active Pharmaceutical Ingredient).
• Hemobrás (Empresa Brasileira de Hemoderivados e Biotecnologia)minorImplementation/ SI/ Consulting Partner · 1 December 2021Hemobrás, through an existing Acordo de Cooperação Técnica, provided its Vice-President of the Commission on Integrity to train Lafepe employees on the Code of Conduct and Integrity, supporting the implementation of Lafepe's compliance program.
• BioCen (Cuba)minorStrategic or Co-development Partner · 1 January 2007Executives from the multinational pharmaceutical company BioCen (Cuba) visited Lafepe to explore a potential partnership. The visit was motivated by Lafepe's consolidation as a national reference in pharmaceutical manufacturing. No formal agreement was confirmed at the time.

Scale indicators12 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• EMS Farmacêutica: Largest Brazilian-owned pharmaceutical company with a broad generic and branded portfolio. Competes for some of the same SUS contracts and Brazilian pharma talent but operates commercially as a private company rather than as a state-owned public-health entity.
• Eurofarma Laboratórios: Large Brazilian pharmaceutical manufacturer with a diversified portfolio across multiple therapeutic areas and active PDP participation. Operates broader commercial operations alongside selective public-sector contracts, overlapping with Lafepe in anti-infectives.
• Cristália Produtos Químicos Farmacêuticos: Major Brazilian pharmaceutical and pharmaceutical-input manufacturer; current PDP partner for Lafepe's Ritonavir production. Competes in similar therapeutic categories (ARVs, public health) with broader commercial ambitions and international presence.
• Aché Laboratórios Farmacêuticos: Leading Brazilian pharmaceutical company with a diversified branded and generic portfolio including CNS, anti-infectives, and consumer health products — adjacent categories to Lafepe's portfolio but commercially led rather than public-health-mandated.

Direct peers

• Iquego - Indústria Química do Estado de Goiás: Goiás state pharmaceutical laboratory operating under a similar public health production model. Supplies the local state health system and SUS with essential medicines, including neglected-disease products.
• Farmanguinhos (Fiocruz): The federal-level public pharmaceutical laboratory under the Oswaldo Cruz Foundation (Fiocruz). Operates the same B2G/government model, producing essential medicines including antiretrovirals for SUS distribution. Closest functional peer to Lafepe at the federal scale — same mandate, similar portfolio across HIV, TB, and neglected diseases.
• Blanver Farmoquímica e Farmacêutica: Brazilian active pharmaceutical ingredient and pharmaceutical manufacturer currently partnered with Lafepe via PDP for Dolutegravir. Operates in the same therapeutic categories (antiretrovirals) with overlapping capabilities in public-health drug production.
• FURP - Fundação para o Remédio Popular: São Paulo state-owned pharmaceutical laboratory producing essential medicines at low cost. Operates with a near-identical public-health mandate and state-government ownership model, directly comparable in scale, B2G/SUS focus, and product portfolio.
• Bahiafarma: Bahia state government pharmaceutical laboratory producing essential medicines for SUS distribution. Same state-ownership model, B2G contract structure, and focus on neglected-disease/public-health medications as Lafepe.
• FUNED - Fundação Ezequiel Dias: Minas Gerais state pharmaceutical foundation serving the same public health production and distribution functions. State-owned entity with comparable manufacturing scope and SUS supply focus, including vaccines and essential medicines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC7QE7ZUP9zaskSOgUXxueQQ
• Facebookfacebook.com/lafepemedicamentos

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lafepe